Key result
Evaluating antiviral compounds requires PLC3 cell differentiation prior to HEV infection.
Differentiation of PLC3 cells before HEV infection may reduce confounding in antiviral assays; leaves open standardization for broader research use.
When infecting PLC3 cell line with HEV for evaluating the antiviral effect of a compound, the PLC3 cells have to be differentiated.
No takes yet. Share an insight, caveat, or question.
Anne Bull-Maurer (2026) studied this question. PLC3 cell differentiation is required prior to HEV infection when evaluating the antiviral effects of compounds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: